



To,
The National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

25th May, 2026

Dear Sir,

Symbol: NIDAN

Sub : Outcome of the Board Meeting held on Monday, 25th May. 2026

Time of Commencement of Board Meeting : 12.30 Hrs.

Time of conclusion of Board Meeting : 17.15 Hrs.

This is to inform you that the Board of Directors of the Company at its Meeting held on May 25, 2026, has inter alia approved the following :

1. Audited Financial Results of the Company for the financial year ended 31st March, 2026;
2. Re-appointment Mr. Nilesh Bide (DIN: 06366702), as an Non Executive- Independent of the Company for the 2nd term of 5 (Five) years w.e.f. 20th August 2026 subject to approval of the shareholders of the Company.
3. Re-appointment of Mr. Abhinay Nerurkar (DIN: 09250964), as an Non Executive- Independent of the Company for the 2nd term of 5 (Five) years w.e.f. 20th August 2026 subject to approval of the shareholders of the Company.
4. Re-appointment of M/s R. K. Chapawat & Co., Chartered Accountants (FRN 101708W) for further period of 5 years.

The details as required under Regulation 30 of SEBI (LODR) Regulations read with SEBI circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023 and updated upto January 30, 2026 is annexed as Annexure A.

This is an intimation under Regulations 30, 33, read with Clause 4(h) of Para A of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").





In this regard, we are enclosing the following:

- (a) Copy of the Audited Financial Results of the Company for the year ended 31st March, 2026, as approved by the Board of Directors today along with the Reports of the Statutory Auditors of the Company on the Financial Results of the Company as **Annexure 'B'**;
- (b) In compliance with the provisions of Regulation 33(3)(d) and 52(3)(a) of the Listing Regulations, a declaration stating that the Statutory Auditors, M/s R. K. Chapawat & Co., Chartered Accountants, have issued the Audit Reports with unmodified opinion on the Financial Results of the Company for the year ended 31st March, 2026 as **Annexure 'C'**;

The extract of Audited Financial Results shall be published in the newspapers in the format prescribed under Regulation 47 of the (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of the Board of Directors commenced at 12.30 Hrs and concluded at 17.15 Hrs on Monday, May 25, 2026.

Kindly take the same on your records.

Thanking you,

Yours Sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN 07984686





Annexure A

The details as required under Regulation 30 of SEBI (LODR) Regulations read with SEBI circular No. SEBI/HO/CFD/POD2/CIR/P/0155 dated November 11, 2024.

1) Re-appointment of Mr. Nilesh Bide (DIN: 06366702) as an Independent Director for his Second term:-

Sr. No.	Particulars	Details
1.	Reason for change viz. Appointment, reappointment, resignation, removal, death or otherwise	Re-appointment as an Independent Director of the Company for the 2 nd term.
2.	Date of Appointment / re-appointment / cessation (as applicable) / term of reappointment	For 5 consecutive years effective August 20, 2026.
3.	Brief profile (in case of appointment)	He is very dynamic post graduate architect by qualification, having keen interest in planning and operation of healthcare centres since 22 Years. He has been instrumental in designing set ups with cost effective consumable cost as well as enhancing efficiency in staff performance.
4.	Disclosure of relationships between directors (in case of appointment of Director)	Not applicable
5.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Nilesh Bide is not debarred from holding the office of Director pursuant to any SEBI order or any other authority.

2) Re-appointment of Mr. Abhinay Nerurkar (DIN: 09250964) as an Independent Director for his Second term:-

Sr. No.	Particulars	Details
1.	Reason for change viz. Appointment, reappointment, resignation, removal, death or otherwise	Re-appointment as an Independent Director of the Company for the 2 nd term.
2.	Date of Appointment / re-appointment / cessation (as applicable) / term of reappointment	For 5 consecutive years effective August 20, 2026.





3.	Brief profile (in case of appointment)	He is business enthusiast having graduation in commerce and post graduate. He has his core competence in managing Profit & Loss as well as extensive experience in manpower training. He has over 20 years of professional experience.
4.	Disclosure of relationships between directors (in case of appointment of Director)	Not applicable
5.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Abhinay Nerurkar is not debarred from holding the office of Director pursuant to any SEBI order or any other authority.

3) Re-appointment of M/s R. K. Chapawat & Co., Chartered Accountants (FRN 101708W) for further period of 5 years

Sr. No.	Particulars	Details
1.	Reason for change viz. Appointment, reappointment, resignation, removal, death or otherwise	Re-appointment as a Statutory Auditor of the Company for a period of 5 years.
2.	Date of Appointment / re-appointment / cessation (as applicable) / term of reappointment	For 5 consecutive years to hold office upto 31 st Annual General Meeting
3.	Brief profile (in case of appointment)	He has over 9 years of professional experience.
4.	Disclosure of relationships between directors (in case of appointment of Director)	Not applicable

Thanking you,

Yours Sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN 07984686





NIDAN LABORATORIES & HEALTHCARE LTD.

ERSTWHILE NIDAN LABORATORIES & HEALTHCARE PVT LTD

25th May, 2026

To,
The National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

Dear Sir,

Symbol: NIDAN

Dear Sir/Madam,

Sub : Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Declaration for audit reports with unmodified opinion(s)

In compliance with the provisions of Regulation 33(3)(d) and 52(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby declares that the Statutory Auditors, Messrs R. K. Chapawat & Co., Chartered Accountants, have issued the Audit Reports with unmodified opinion on the Financial Results of the Company for the Financial Year ended 31st March, 2026.

Thanking you,

Yours Sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN 07984686



Swarnashilp, Behind Aarti Apt.
Vartak Road, Virar (West),
401303, Mumbai, India.



L33111MH2000PLC129883



19.45707, 72.81031



1800 2 333 999



+91 96576 41000



www.nidanhealthcare.co.in

Connect with us on :



Nidan Laboratories And Healthcare Limited
CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303

Tel No. +91 8975610000, E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of Audited Financial Results for the Half Year and Year Ended as on 31st March 2026

Rs in lakhs

	Particulars	Half Year ended			Year Ended	Year Ended
		31-Mar-26 Audited	30-Sep-25 Unaudited	31-Mar-25 Audited	31-Mar-26 Audited	31-Mar-25 Audited
1	Income					
	a) Revenue from Operations	1,242.06	1,312.10	1,399.48	2,554.16	2,452.75
	b) Other Income	68.61	116.96	121.97	185.57	225.06
	Total Income (a+b)	1,310.67	1,429.06	1,521.45	2,739.73	2,677.81
2	Expenses					
	a) Cost of Materials Consumed	57.92	40.35	54.16	98.27	102.15
	b) Changes in inventories of Finished Goods, Work in Progress and Stock-in-Trade	0.46	1.26	(23.73)	1.72	(24.52)
	c) Employee benefit expenses	218.46	211.77	267.74	430.23	451.56
	d) Finance Costs	107.16	88.48	126.45	195.64	214.38
	e) Depreciation and Amortization expenses	97.52	92.26	107.31	189.78	240.86
	f) Other Expenses	735.10	804.61	854.88	1,539.71	1,417.36
	Total Expenses (a to f)	1,216.62	1,238.74	1,386.81	2,455.35	2,401.79
3	Profit before Exceptional and Extraordinary Items & Tax	94.05	190.32	134.64	284.38	276.02
4	Exceptional & Extraordinary Items	40.00	-	-	40.00	-
5	Profit before Tax and after exceptional & extraordinary item (3-4)	54.05	190.32	134.64	244.38	276.02
6	Tax Expenses					
	a) Current Tax	21.50	43.50	29.00	65.00	65.00
	b) Deferred Tax Asset/Liability	9.92	3.45	9.82	13.37	5.07
	c) Tax of earlier year	15.41	-	8.26	15.41	8.26
	Total tax expenses	46.83	46.95	47.08	93.77	78.33
7	Profit for the period / year	7.22	143.37	87.56	150.60	197.69
8	Paid-up equity share capital (Face value of Rs 10/- per share)	1,390	1,390	1,390	1,390	1,390
9	Earnings Per Share (not annualized for the half year ended)					
	a) Basic EPS	0.05	1.03	0.63	1.08	1.42
	b) Diluted EPS	0.05	1.03	0.63	1.08	1.42

Notes:

- The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 25th May 2026.
- The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsory adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February, 2015 issued by ministry of corporate affairs.
- The Company does not have different segments and hence segment wise reporting is not applicable to the Company.
- The figures of the corresponding previous half year have been regrouped/rearranged wherever considered necessary to make them comparable



For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

F. Anil Jayakar
Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 25th May 2026
Place : Mumbai

Nidan Laboratories And Healthcare Limited
Statement Of Cash Flows for the year ended 31st March 2026

Rs. in lakhs

Particulars	Year ended	
	31st March 2026	31st March 2025
A - CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	244.38	276.02
Add/ (less) Adjustment for:		
Interest Income	(182.57)	(204.63)
Interest Expenses	167.66	180.91
Interest on income tax	18.39	25.71
Sundry balance written back	(2.34)	(16.83)
Depreciation on property plant & equipment	189.78	240.86
(Gain)/loss on disposal of property, plant and equipment	-	(3.16)
Operating Profit Before Working Capital Changes	435.29	498.88
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	(94.90)	(74.35)
(Increase)/ decrease in Other Current Assets	(29.43)	(55.13)
(Increase) / decrease in Inventories	1.72	(24.52)
Increase / (decrease) in Trade payables	(16.54)	30.37
Increase / (decrease) in Other current Liability	(6.70)	15.42
Increase / (decrease) in Short Term Provision	(3.27)	2.55
Increase / (decrease) in Long term Provisions	(20.23)	2.85
Cash Generated from Operations	265.93	396.08
Add/ (less) : Direct taxes paid (net of refund received)	(99.22)	(160.08)
Net Cash Inflow / (outflow) from Operating Activities	166.71	236.00
B - CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment / intangible assets / Capital work in progress	(47.67)	(94.02)
Investment in group company	-	(2,000.00)
Proceeds from sale of property, plant and equipment	-	6.67
(Increase) / decrease in long term security deposit	(5.35)	0.91
(Increase) / Decrease in Long term loans and advances (net)	92.13	12.85
(Increase) / decrease in Short Term Loans and Advances	(203.82)	1,982.79
Interest received	170.83	69.76
Net cash inflow/(outflow) from Investing Activities	6.12	(21.06)
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	5.33	(119.83)
Increase / (decrease) in Long term security deposit liability	(1.00)	(9.25)
Interest Expenses	(167.66)	(180.91)
Net Cash inflow/(outflow) from Financing Activities	(163.33)	(309.98)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	9.50	(95.05)
Add: Cash and Cash Equivalents at the beginning of the year	189.95	284.99
Cash and Cash Equivalents at the end of the year	199.45	189.94

Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows :

Particulars	As at	
	31st March 2026	31st March 2025
Cash on hand	81.27	186.78
Balances with Banks	118.18	3.16
Cash and Cash Equivalents	199.45	189.94



For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

F.A. Jayakar
Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686

Date : 25th May 2026
Place : Mumbai

Nidan Laboratories And Healthcare Limited
Statement of Assets & Liabilities as at 31st March 2026

Rs in lakhs

	As at 31st March 2026 (Audited)	As at 31st March 2025 (Audited)
Particulars		
I Equity & Liabilities		
1. Shareholders' funds		
Equity Share Capital	1,390.00	1,390.00
Reserves and Surplus	5,578.90	5,428.30
	6,968.90	6,818.30
2. Non - Current Liabilities		
(a) Long - Term Borrowings	363.50	389.51
(b) Other Long term liabilities	6.39	7.39
(c) Long Term Provisions	39.10	59.33
	408.99	456.23
3. Current Liabilities		
(a) Short - Term Borrowings	752.88	721.53
(b) Trade Payables		
(i) Total outstanding due of micro enterprises and small enterprises and small enterprises	8.20	30.78
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	69.19	65.49
(c) Other Current Liabilities	136.01	142.72
(d) Short - Term Provisions	55.37	59.05
	1,021.65	1,019.57
TOTAL	8,399.54	8,294.10
II Assets		
1. Non - Current Assets		
(a) Property Plant & Equipment and Intangible Assets		
(i) Property, Plant & Equipments	1,489.69	1,631.94
(ii) Intangible Asset	1.45	1.31
(iii) Capital workin progress	15.11	15.11
(b) Non-Current Investments	2,000.00	2,000.00
(c) Long - Term Loans and Advances	3,299.37	3,379.76
(d) Deferred Tax Asset (Net)	63.50	76.87
(e) Other Non Current Assets	74.25	68.90
	6,943.37	7,173.89
2. Current Assets		
(a) Inventories	52.99	54.71
(b) Trade Receivables	221.68	126.79
(c) Cash and Cash Equivalents	199.45	189.94
(d) Short - Term Loans and Advances	636.36	432.54
(e) Other Current Assets	345.69	316.23
	1,456.17	1,120.21
TOTAL	8,399.54	8,294.10



For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

G. A. Jayakar
Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 25th May 2026
Place : Mumbai

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Extract of Audited Financial Results for the half year and Year ended on 31st March 2026

Rs in lakhs

S.No	Particulars	Half Year Ended 31st March 2026 (Audited)	Half Year Ended 30th September 2025 (Unaudited)	Half Year Ended 31st March 2025 (Audited)	Year Ended 31st March 2026 (Audited)	Year Ended 31st March 2025 (Audited)
1	Total Income from Operations	1,242.06	1,312.10	1,399.48	2,554.16	2,452.75
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	94.05	190.32	134.64	284.38	276.02
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	54.05	190.32	134.64	244.38	276.02
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	7.22	143.37	87.56	150.60	197.69
5	Total Comprehensive income for the period /year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)]	7.22	143.37	87.56	150.60	197.69
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (exluding revaluation reserve)				5,578.90	5,428.30
8	Earnings Per Share (of Rs 10/-each) (not annualized for the half year ended)					
	Basic	0.05	1.03	0.63	1.08	1.42
	Diluted	0.05	1.03	0.63	1.08	1.42

1) The above is an extract of Audited Financial Results for half year and year ended 31st March 2026 which have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at the meeting held on 25th May 20256 and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period.



**For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited**

(Signature)
**Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686**

Date : 25th May 2026
Place : Mumbai



R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Report on the half-year and year ended 31st March, 2026 financial results of the Nidan Laboratories and HealthCare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation's, 2015 (As Amended)

To,
The Board of Directors of
Nidan Laboratories and HealthCare Limited

Opinion

We have audited the accompanying financial results of Nidan Laboratories and HealthCare Limited ("the Company") for the half year ended 31st March, 2026 and for the year ended 31st March 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year ended 31st March, 2026 and for the year ended 31st March 2026.

Basic for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



R.K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Management's and Board of Directors Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Company's Management & Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to



R.K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher, than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in due financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in the manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



R.K. CHAPAWAT & CO. CHARTERED ACCOUNTANTS

Other Matters

The Statement includes the results for the half year ended 31st March, 2026 being the balancing figure between audited figures in respect of the full financial year and the published unaudited years-to-date figures up to the Half year (30th September, 2025) of the current financial year which were subject to limited review by us. As required under the Listing Regulations. Our report or the Statement is not modified in respect of this matter.

For R. K. Chapawat & Co.
Chartered Accountants
Firm Registration no. 101708W

K. Chapawat

Kamlesh Chapawat
Partner
Membership No.: 181441
Udin No.: 26181441UUNSKW5757
Place: Mumbai
Date: 25th May 2026

